Converting to Eylea from Avastin may benefit Patients with Diabetic Macular Edema

(c) British Journal of Ophthalmology

A study from Portugal, published in Graefe's Archive for Clinical and Experimental Ophthalmology, finds changing from bevacizumab (avastin) to aflibercept (eylea) for persistent diabetic macular edema resulted in functional and anatomical improvements. Central macular thickness previous to starting aflibercept was found to be a predictor of anatomical changes after aflibercept.

Suprachoroidal injection - Clearside's approach to treating Diabetic Macular Edema

(c) NEI

Clearside Biomedical, Inc. has completed patient enrollment in the Phase 2 clinical trial (referred to as "TYBEE") of CLS-TA, the company's proprietary suspension formulation of the corticosteroid triamcinolone acetonide (TA) for suprachoroidal administration, used in combination with intravitreally administered Eylea^TM (aflibercept) for treatment of diabetic macular edema (DME).  Patient follow-up in the TYBEE trial is 6 months.